For research use only. Not for therapeutic Use.
Droxidopa(CAT: I013939) is a pharmaceutical compound widely used in the treatment of neurogenic orthostatic hypotension (NOH). As a prodrug of norepinephrine, it is converted enzymatically in the body to restore norepinephrine levels, improving blood pressure regulation and alleviating symptoms of dizziness and lightheadedness. Droxidopa’s unique mechanism of action targets the autonomic nervous system, making it valuable for research into autonomic disorders and cardiovascular regulation. Its role in enhancing norepinephrine availability also provides insights into the management of fatigue and related neurological conditions, offering a versatile tool for therapeutic studies and drug development.
| Catalog Number | I013939 |
| CAS Number | 23651-95-8 |
| Molecular Formula | C₉H₁₁NO₅ |
| Purity | ≥95% |
| Target | Phenylpropanoids |
| Solubility | DMSO: 1.8 mg/mL (Need ultrasonic and warming) |
| IUPAC Name | (2S,3R)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid |
| InChI | InChI=1S/C9H11NO5/c10-7(9(14)15)8(13)4-1-2-5(11)6(12)3-4/h1-3,7-8,11-13H,10H2,(H,14,15)/t7-,8+/m0/s1 |
| InChIKey | QXWYKJLNLSIPIN-JGVFFNPUSA-N |
| SMILES | C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O |
